| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/26/2001 | WO2001053541A1 Antisense modulation of caspase 8 expression |
| 07/26/2001 | WO2001053518A2 Method of assessing the viability of a cell |
| 07/26/2001 | WO2001053506A2 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | WO2001053505A2 Herpes virus strains for gene therapy |
| 07/26/2001 | WO2001053493A2 Human kinase protein and polynucleotides encoding the same |
| 07/26/2001 | WO2001053489A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | WO2001053486A1 Compositions and methods for the treatment of tumor |
| 07/26/2001 | WO2001053469A2 Phosphatases |
| 07/26/2001 | WO2001053461A1 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 07/26/2001 | WO2001053351A2 Apoptin bindendes protein |
| 07/26/2001 | WO2001053348A2 Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them |
| 07/26/2001 | WO2001053343A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053342A1 Chimeric prostate-homing peptides with pro-apoptotic activity |
| 07/26/2001 | WO2001053321A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 07/26/2001 | WO2001053313A1 Antisense modulation of smad7 expression |
| 07/26/2001 | WO2001053311A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| 07/26/2001 | WO2001053310A1 Antisense modulation of caspase 3 expression |
| 07/26/2001 | WO2001053295A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 07/26/2001 | WO2001053294A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| 07/26/2001 | WO2001053293A1 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| 07/26/2001 | WO2001053291A1 Benzimidazole derivatives |
| 07/26/2001 | WO2001053289A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound |
| 07/26/2001 | WO2001053280A1 Substituted phenylamidines medicaments containing said compounds and method for production thereof |
| 07/26/2001 | WO2001053279A1 Urea compounds as inhibitors for vla-4 |
| 07/26/2001 | WO2001053278A1 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors |
| 07/26/2001 | WO2001053274A1 Amide compounds for inhibiting protein kinases |
| 07/26/2001 | WO2001053272A1 Human chymase inhibitors |
| 07/26/2001 | WO2001053271A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 07/26/2001 | WO2001053268A2 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 07/26/2001 | WO2001053267A1 Compounds exhibiting thrombopoietin receptor agonism |
| 07/26/2001 | WO2001053266A1 Therapeutic morpholino-substituted compounds |
| 07/26/2001 | WO2001053263A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | WO2001053262A1 Alpha v integrin receptor antagonists |
| 07/26/2001 | WO2001053261A1 Substituted glutarimides and use thereof il-12 production inhibitors |
| 07/26/2001 | WO2001053255A1 Gamma-secretase inhibitors |
| 07/26/2001 | WO2001053254A1 Calcilytic compounds |
| 07/26/2001 | WO2001052903A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | WO2001052902A1 Antisense modulation of inducible nitric oxide synthase expression |
| 07/26/2001 | WO2001052893A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis |
| 07/26/2001 | WO2001052892A2 Jak/stat pathway inhibitors and the uses thereof |
| 07/26/2001 | WO2001052880A1 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| 07/26/2001 | WO2001052878A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 07/26/2001 | WO2001052870A1 Treatment of congestive heart failure by pretreated autologous blood |
| 07/26/2001 | WO2001052866A1 Dextrin containing compositions for prevention of adhesions |
| 07/26/2001 | WO2001052865A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 07/26/2001 | WO2001052862A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | WO2001052856A2 Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action |
| 07/26/2001 | WO2001052855A2 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| 07/26/2001 | WO2001052849A1 Remedies for diabetes |
| 07/26/2001 | WO2001052845A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | WO2001052844A1 Brain, spinal and nerve injury treatment |
| 07/26/2001 | WO2001052837A2 Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 07/26/2001 | WO2001052826A2 Novel podophyllotoxin compositions |
| 07/26/2001 | WO2001052825A2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/26/2001 | WO2001052821A1 Improved pharmaceutical formulations |
| 07/26/2001 | WO2001022944A8 Oral controlled release formulations |
| 07/26/2001 | WO2001015726A3 Compositions for stimulating cytokine secretion and inducing an immune response |
| 07/26/2001 | WO2001014886A3 Inhibitors of binding between proteins and macromolecular ligands |
| 07/26/2001 | WO2001014415A3 Egfh2 genes and gene products |
| 07/26/2001 | WO2001008663A3 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 07/26/2001 | WO2001004264A3 Atherosclerosis-associated genes |
| 07/26/2001 | WO2001001748A3 Peptide compounds that bind her2 |
| 07/26/2001 | WO2000071741A9 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 07/26/2001 | WO2000070341A3 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 07/26/2001 | WO2000066156A8 Death domain containing receptor 5 |
| 07/26/2001 | WO2000055194A9 Tuberculosis antigens and methods of use therefor |
| 07/26/2001 | WO2000044356A9 Hydrogel compositions useful for the sustained release of macromolecules and methods of making same |
| 07/26/2001 | US20010009995 Oxybutynin therapy |
| 07/26/2001 | US20010009921 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 07/26/2001 | US20010009920 Combination therapy for osteoporosis |
| 07/26/2001 | US20010009919 Tris benzimidazoles; fungicides, anticarcinogenic agents, enzyme inhibitor |
| 07/26/2001 | US20010009915 Nitrogen oxide yielding and thromboxane A2 (TXA2) and serotonin (5HT2) receptor antagonist; treatment of atherothrombotic cardiovascular disorders |
| 07/26/2001 | US20010009911 Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress |
| 07/26/2001 | US20010009906 Treatment of HIV-infected human in alternation or combination with second anti-HIV drug that induces mutation pattern at other than 70th codon of reverse transcriptase region location; drug resistance, pharmokinetics |
| 07/26/2001 | DE19953167A1 Mit TRP-Proteinen verwandtes Protein MTR1 und dieses codierende DNA-Sequenz With TRP proteins related protein MTR1 and this DNA sequence encoding |
| 07/26/2001 | DE10002510A1 New phenylamidine compounds are useful for the treatment of thrombosis, cerebrovascular disorders, heart infarction, arteriosclerosis, osteoporosis, tumor metastasis, shock and diabetes |
| 07/26/2001 | DE10002509A1 New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
| 07/26/2001 | DE10001172A1 Templatieren von Feststoffpartikeln mit Polymermultischichten Templating of solid particles with polymer multilayers |
| 07/26/2001 | DE10000651A1 Identifying inhibitors and activators of eukaryotic potassium channels, for use as pharmaceuticals, comprises using yeast cells that express heterologous, but no endogenous, potassium channels |
| 07/26/2001 | DE10000577A1 Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity |
| 07/26/2001 | CA2673615A1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/26/2001 | CA2398343A1 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | CA2398239A1 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 07/26/2001 | CA2398086A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis |
| 07/26/2001 | CA2398061A1 Substituted glutarimides and their use as inhibitors of il-12 production |
| 07/26/2001 | CA2397871A1 Novel podophyllotoxin compositions |
| 07/26/2001 | CA2397802A1 Calcilytic compounds |
| 07/26/2001 | CA2397783A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | CA2397774A1 Jak/stat pathway inhibitors and the uses thereof |
| 07/26/2001 | CA2397686A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | CA2397665A1 Alpha v integrin receptor antagonists |
| 07/26/2001 | CA2397633A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | CA2397617A1 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 07/26/2001 | CA2397571A1 Apoptin-associating protein |
| 07/26/2001 | CA2397543A1 Gamma-secretase inhibitors |
| 07/26/2001 | CA2397533A1 Substituted phenylamidines, pharmaceutical compositions containing these compounds and processes for preparation thereof |
| 07/26/2001 | CA2397492A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | CA2397202A1 Antisense modulation of glycogen synthase kinase 3 alpha expression |
| 07/26/2001 | CA2397065A1 Compositions for delivery of a cortisol antagonist |
| 07/26/2001 | CA2396935A1 Phosphatases |